Navigation Links
Collexis Connects the NIH Clinical and Translational Science Award Programs with CTSA Expert Platform

COLUMBIA, S.C., March 3 /PRNewswire-FirstCall/ -- Collexis Holdings Inc. (OTC Bulletin Board: CLXS), a leading developer of semantic search and knowledge discovery software, announced today the launch of the world's first CTSA Experts Platform drawing on the research profiles of 38 institutions and their more than 60,000 life science researchers. The platform is available to Collexis clients who are also winners of the Clinical Translational Science Awards (CTSA's) from the National Institutes of Health. Institutions that are subscribers to the service will be able to search, rank, and visualize expert profiles from all 38 CTSA institutions.

(Logo: )

"Among the goals of the National Institutes of Health CTSA awards are to accelerate bench to bedside discoveries into patient care, as well as to develop the infrastructure to support ongoing collaborative efforts in biomedical research," said Dr. Christian Herzog, Managing Director at Collexis. "The Collexis CTSA Expert Platform will allow participants to achieve these important goals by matching basic researchers and clinical scientists within organizations, and across multiple awarded institutions."

The new offering gives CTSA users a unique competitive advantage. It allows a researcher to identify partners from their organization and across the CTSA Consortia on any biomedical research topic(s). The platform automatically recommends collaborators from other institutions based on multiple areas of common research interests. Finally, the system will track and identify collaboration patterns among CTSA consortia members, allowing Collexis to give clients and NIH more information about how researchers work together and signaling ways that NIH can improve the CTSA program.

The Collexis Expert Platform approach to profiling life science researchers has become the standard with research intensive institutions. Current clients include Johns Hopkins, the National Institutes of Health, University of Michigan, Oregon Health Sciences University, The Medical College of Georgia, The University of Miami, the University of South Carolina, and over 25 more leading medical research institutions.

About Collexis Holdings, Inc.

Collexis Holdings, Inc., a leading developer of semantic search and knowledge discovery software is headquartered in Columbia, South Carolina (USA) with operations in Cincinnati, Ohio and Cologne, Germany. Collexis now offers the world's first pre-populated scientific social network for life science researchers, Collexis' proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, Websites, emails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis' current clients in the public, private and academic sectors include the Mayo Clinic; Johns Hopkins University; Dana-Farber Cancer Institute, the University of California, San Francisco; the University of South Carolina; Erasmus University Library; Bristol-Myers Squibb; Lockheed Martin; the World Health Organization; Wellcome Trust; the National Institutes of Health; and the U.S. Department of Defense. Shares of Collexis common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information, visit

Disclaimer: National Institutes of Health (NIH) is not considered a supporter or partner of Collexis. Reference to NIH in the above shall not be construed as a Government endorsement nor does it obligate NIH to a position on or about the Collexis Software.

Forward-Looking Statements

Some of the statements made in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and include known and unknown risks, uncertainties and other factors, many of which the company is unable to predict or control, that may cause the company's actual results or performance to differ materially from any future results or performance expressed or implied by such forward-looking statements. These statements involve risks and uncertainties, including risks and uncertainties associated with the company's CTSA Experts Platform. These risks and uncertainties are in addition to other factors detailed from time to time in the company's filings with the SEC, including the section entitled "Risk Factors" in its transition report on Form 10-K for the period ended June 30, 2008. The company cautions investors that any forward-looking statements made by the company are not necessarily indicative of future performance. The company is not responsible for updating the information contained in this press release beyond the published date, or for changes made to this document by wire services or Internet services.

SOURCE Collexis Holdings Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. American Association for Cancer Research (AACR) Deploys Collexis Reviewer Finder and Journal Dashboard Applications
2. BioFlorida Selects Collexis as the Primary Professional Network for its 200 Member Companies and Organizations
3. Carbon nanotubes outperform copper nanowires as interconnects
4. Clinical Research Staffing Firm ASG Acquires CRO Ockham Development Group
5. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
6. Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain
7. Implicit Licenses Clinical Stage Antibody Program From Lilly
8. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
9. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
10. Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes
11. M2S Expert gives address "Applying the Principles of Six Sigma in the Imaging Core Lab" at Imaging for Clinical Trials conference
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, ... will participate in a fireside chat discussion at the ... New York . The discussion is scheduled for ... .  A replay will be available ... Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications and ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association (USGA) ... USGA Green Section Award. Presented annually since 1961, the USGA Green Section Award recognizes ... with turfgrass. , Clarke, of Iselin, N.J., is an extension specialist of ...
(Date:11/24/2015)... ... 24, 2015 , ... Copper is an essential micronutrient that ... proteins, copper is also toxic to cells. With a $1.3 million award from ... conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. aeruginosa), ...
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris , qui ... Paris , qui s,est tenu du ... leader de l,innovation biométrique, a inventé le premier scanner ... sur la même surface de balayage. Jusqu,ici, deux scanners ... les empreintes digitales. Désormais, un seul scanner est en ...
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has entered ... MIT and Harvard for use of its ArxLab ... management tools. The partnership will support the institute,s ... and chemical research information internally and with external ... used for managing the Institute,s electronic laboratory notebook, ...
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
Breaking Biology News(10 mins):